September 26, 2024
Confronting the World’s Leading Killer with a New Therapeutic Approach
For Xicang Guo and Jiaming Zhang, one particular condition remains stubbornly beyond their control – hypertension, also known as high blood pressure.
Read More ›
September 12, 2024
RNAi Therapeutics, from Possibility to Patients
The story of an innovative approach to silencing disease that’s improving lives and changing expectations for medicine.
Read More ›
September 10, 2024
Alnylam Named a Best Workplace for Innovators for the 4th Year in a Row by Fast Company
Alnylam has been named a Fast Company Best Workplace for Innovators for 2024, our 4th year in a row on the list.
Read More ›
August 15, 2024
Alnylam Named a Humankind 100 Company for the 3rd Year in a Row
Alnylam has been named to the HumanKind 100 list for the 2nd year in a row and we’re pleased to have moved up in the rankings from #97 in 2022 to #76 in 2023.
Read More ›
May 7, 2024
Alnylam Publishes 2023 Corporate Responsibility Report
Alnylam's 2023 Corporate Responsibility Report details our corporate responsibility and ESG efforts and progress.
Read More ›
April 26, 2024
Better Together: Alnylam and Organized Customer Health Systems Want to Improve Access and ...
Alnylam's Head of Strategic Accounts discusses the rise of the Integrated Delivery Network and manufacturer relationship
Read More ›
April 25, 2024
Our Commitment to Patients Means Never Stop Evolving - Our Patient Access Philosophy
Tolga Tanguler, Alnylam's Chief Commercial Officer discusses Alnylam's Patient Access Philosophy and approach to access
Read More ›
April 16, 2024
Alnylam Ranked #3 on LinkedIn's List of Top Midsize Companies for 2024
Alnylam is proud to be included on LinkedIn's Top Companies list for 2024.
Read More ›
April 2, 2024
2023 Year in Review: CEO Yvonne Greenstreet Reflects on a Year of Substantial Growth and P ...
Alnylam CEO Yvonne Greenstreet reflects on the company's accomplishments in 2023 and highlights of the 2023 annual report.
Read More ›
February 29, 2024
Alnylam Named to Human Rights Campaign’s Corporate Equality Index
Alnylam has achieved a score of 90 out of 100 on the Human Rights Campaign's (HRC) 2023-2024 Corporate Equality Index (CEI) based on our US policies, practices,
Read More ›
The following content may not be associated with Alnylam Pharmaceuticals.
Links to all outside sites are provided as a reference for our visitors.
Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.
Proceed to Site